spacer
home > pmps > summer 2017 > heating up
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Heating Up

One cannot complain that cold chain for the pharmaceutical and biotechnology industries is lacking challenges – shipping products globally by airplanes or ocean freighters, for instance, is a hot discussion topic. This obstacle is not new for products and vaccines shipped in the 2-8°C range, but for other expanses, like 15-25°C, it has a considerable impact.

Almost 50% of temperature excursions take place on the tarmac of an airport; thus, a compliant shipment is important. The only way to maintain product quality is to keep it in prescribed conditions until the moment of use. No patient can benefit from an expired treatment or an inaccurate blood sugar level measurement because the strips were not kept in the right conditions. Even worse, products could become harmful instead of helpful.

From a cost perspective, as well as a qualitative one, the use of ocean freight is transcending that of air transport. Ocean shipping is not only considered for low-value products, but also for high-value ones, such as vaccines.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Martin Gouda is a Partner of Supply Chain Strategies at Buck Consultants International and has over 30 years of experience in international supply chain optimisation. He has worked in various roles at the strategic and tactical level in management and consultancy. Martin worked for a global 3PL for almost 10 years in various business development positions. In this period, he was responsible for breakthrough and step change projects with pharma companies. In the last three years, he was leading the healthcare sector on a global level. Martin is co-founder and board member of the Healthcare Logistics Forum. 
spacer
Martin Gouda
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Mologic Signs Agreements with Medisur and Peripal to Distribute PERiPLEX POC Diagnostic in Europe

Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, today announced that it has signed agreements with medical technology companies, Medisur and Peripal AG to distribute PERiPLEX®, a rapid point-of-care (POC) test for the detection of infection in patients on peritoneal dialysis (PD). Both companies are specialists in the development and distribution of products which enable patient self-management and will supply PERiPLEX as part of a highly complementary product portfolio in key European markets including France, Germany, Italy, The Netherlands, Austria and Switzerland.
More info >>

White Papers

ConsulTech GmbH

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
More info >>

 
Industry Events

SMi’s 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement